Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC
作者： Federico Cappuzzo , Vanesa Gregorc , Elisa Rossi , Alessandra Cancellieri , Elisabetta Magrini
关键词:
摘要: Purpose: To evaluate the correlation between HER2 expression and gefitinib (ZD 1839, Iressa; AstraZeneca, London, United Kingdom) efficacy in terms of response rate, time to progression (TTP), overall survival (OS) time. Patients Methods: with pretreated advanced non–small-cell lung cancer (NSCLC) received at a daily dose 250 mg until disease progression. Tumor tissue specimens obtained primary diagnosis were collected determine HER2/epidermal growth factor receptor (EGFR) status by immunohistochemistry. Results: From February 2001 June 2002, 63 consecutive patients enrolled onto study. The control rate was 58.7% (partial [PR], 15.9%; stable [SD], 42.8%), median TTP 3.3 months, OS 4.1 months. Among 43 whom EGFR/HER2 determined, we observed six PRs (14%) 18 SDs (42%). Disease control, including PR SD, 40% 15 overexpressing 64.3% t...
elsevier.com
sci-hub.se 参考文章(26)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Shyh-Min Huang, Paul M. Harari, Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Investigational New Drugs. ,vol. 17, pp. 259- 269 ,(1999) , 10.1023/A:1006384521198
Leah N. Klapper, Mark H. Kirschbaum, Michael Seta, Yosef Yarden, Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors Advances in Cancer Research. ,vol. 77, pp. 25- 79 ,(1999) , 10.1016/S0065-230X(08)60784-8
Julie M. Cherrington, Randall E. Schreck, Dirk B. Mendel, Jean Cui, James G. Christensen, Emily Chan, Chris Yang, James Wei, Luna Liu, Li Sun, Xueyan Wang, High Levels of HER-2 Expression Alter the Ability of Epidermal Growth Factor Receptor (EGFR) Family Tyrosine Kinase Inhibitors to Inhibit EGFR Phosphorylation in Vivo Clinical Cancer Research. ,vol. 7, pp. 4230- 4238 ,(2001)
Mark M. Moasser, Steven D. Averbuch, Neal Rosen, Andrea Basso, The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells Cancer Research. ,vol. 61, pp. 7184- 7188 ,(2001)
D. Karunagaran, E. Tzahar, R. R. Beerli, X. Chen, D. Graus-Porta, B. J. Ratzkin, R. Seger, N. E. Hynes, Y. Yarden, ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer The EMBO Journal. ,vol. 15, pp. 254- 264 ,(1996) , 10.1002/J.1460-2075.1996.TB00356.X
Karen Kelly, John Crowley, Paul A. Bunn, Cary A. Presant, Patra K. Grevstad, Carol M. Moinpour, Scott D. Ramsey, Antoinette J. Wozniak, Geoffrey R. Weiss, Dennis F. Moore, Valerie K. Israel, Robert B. Livingston, David R. Gandara, Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial Journal of Clinical Oncology. ,vol. 19, pp. 3210- 3218 ,(2001) , 10.1200/JCO.2001.19.13.3210
L. Crinò, G. V. Scagliotti, S. Ricci, F. De Marinis, M. Rinaldi, C. Gridelli, A. Ceribelli, R. Bianco, M. Marangolo, F. Di Costanzo, M. Sassi, S. Barni, A. Ravaioli, V. Adamo, L. Portalone, G. Cruciani, A. Masotti, G. Ferrara, F. Gozzelino, M. Tonato, Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project Journal of Clinical Oncology. ,vol. 17, pp. 3522- 3530 ,(1999) , 10.1200/JCO.1999.17.11.3522
E.F. Smit, J.P. van Meerbeeck, P. Lianes, F. Schramel, G. Lenz, An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer European Journal of Cancer. ,vol. 37, ,(2001) , 10.1016/S0959-8049(01)81053-4
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25